Mantle cell lymphoma is described in the packet's definition as a rare form of malignant non-Hodgkin lymphoma affecting B lymphocytes in the lymph nodes in a region called the mantle zone. Prevalence is categorized as uncommon, at approximately 1 to 9 per 100,000 people. The packet lists no associated genes, and inheritance patterns and age of onset are not certified in this packet. Listed subtypes include gastric mantle cell lymphoma and splenic mantle cell lymphoma.

The packet lists nine phenotype annotations with HPO frequency labels. Lymphadenopathy and B-cell lymphoma are each annotated as very frequent (80-99%). Fatigue, splenomegaly, anorexia, abnormal bone marrow cell morphology, fever, and weight loss are each annotated as frequent (30-79%). Abnormality of the gastrointestinal tract is annotated as occasional (5-29%). Severity, progression, and age of onset are not certified in this packet.

The packet lists no associated genes and no inheritance patterns, so the genetic basis and any pattern of inheritance are not certified here.

Diagnostic methods and criteria are not certified in this packet.

According to the packet's approved-treatment records, the following products have FDA approval with an ACTIVE market status: BRUKINSA (zanubrutinib; approved 2025-06-10), BORUZU (bortezomib; 2024-08-26), JAYPIRCA (pirtobrutinib; 2023-01-27), IMBRUVICA (ibrutinib; 2022-08-24), CALQUENCE (acalabrutinib; 2022-08-03), Tecartus (brexucabtagene autoleucel; 2020-07-24), REVLIMID (lenalidomide; 2005-12-27), and VELCADE (bortezomib; 2003-05-13). Tecartus is recorded as a cell therapy regulated by FDA's Center for Biologics Evaluation and Research; the others are recorded as NDA products. A separate bortezomib record carries a DISCONTINUED market status and is not a current option. The packet's orphan-drug listing records mantle cell lymphoma as the indication for Velcade, Tecartus, Imbruvica, Revlimid, Calquence, Jaypirca, and Brukinsa; an indication for BORUZU is not specified in the packet. The same listing records Breyanzi with status APPROVED, but it is absent from the packet's approved-treatment records, so its approval is not certified here. Several other products in the listing carry DESIGNATED or WITHDRAWN status; orphan designation is not FDA approval. Eligibility, stage-specific treatment context, and foundational therapies are not certified in this packet. The packet also records a HealthWell Foundation program, the Mantle Cell Lymphoma Fund, with premium and copay assistance and an enrollment status of accepting.

Prognosis and natural history are not certified in this packet.

According to ClinicalTrials.gov records summarized in the packet, numerous trials are associated with this condition. Examples include NCT05861050, a Phase 1 study of glofitamab with obinutuzumab, venetoclax, and lenalidomide in newly diagnosed high-risk mantle cell lymphoma, sponsored by City of Hope Medical Center (recruiting; 2023-08-10 to 2027-02-01); NCT04545762, a Phase 1 study of anti-CD19 chimeric antigen receptor T cells in relapsed or refractory non-Hodgkin lymphoma, sponsored by C. Babis Andreadis (recruiting; 2020-09-11 to 2026-10-31); NCT06533579, a Phase 1 gene therapy study for CD19-positive hematologic malignancies, sponsored by Vironexis Biotherapeutics (recruiting; 2025-05-30 to 2031-09-01); and NCT03147885, a Phase 1 study of selinexor plus combination chemotherapy in advanced B cell non-Hodgkin lymphoma, sponsored by the Barbara Ann Karmanos Cancer Institute (active, not recruiting; 2017-06-20 to 2027-06-25). Trial titles do not establish the effect of any intervention. A ClinicalTrials.gov search link is included in the packet.